Samsung Biologics (Korea) Investor Sentiment

207940 Stock   929,000  29,000  3.03%   
About 61% of Samsung Biologics' investor base is looking to short. The analysis of current outlook of investing in Samsung Biologics Co suggests that many traders are alarmed regarding Samsung Biologics' prospects. The current market sentiment, together with Samsung Biologics' historical and current headlines, can help investors time the market. In addition, many technical investors use Samsung Biologics stock news signals to limit their universe of possible portfolio assets.
  
over six months ago at news.google.com         
Public companies who have a significant stake must be disappointed along with institutions after Sam...
Google News at Macroaxis
over six months ago at news.google.com         
Samsung heir Lee acquitted of stock manipulation charges - The Register
Google News at Macroaxis
over six months ago at news.google.com         
The rise in stock prices of Samsung Biologics, which has been locked in the box for three years, is ...
Google News at Macroaxis
over six months ago at news.google.com         
Rapid Micro Biosystems Shares Rise After Samsung Biologics Partnership - Morningstar
Google News at Macroaxis
over six months ago at news.google.com         
Samsung Biologics Industry news to be important amid easing valuations - BusinessKorea
Google News at Macroaxis
over six months ago at news.google.com         
Samsung Bioepis, Intocell partner for ADC drug development - BioWorld Online
Google News at Macroaxis
over six months ago at news.google.com         
Samsung Biologics engages suppliers to advance global ... - Marketscreener.com
Google News at Macroaxis
over six months ago at news.google.com         
BMS Expands Cardio Partnership with Avidity in Potential 2.3B Deal - BioSpace
Google News at Macroaxis
over a year ago at news.google.com         
5-yr sentence sought for Samsung chief in connection with ... - Yonhap News Agency
Google News at Macroaxis
over a year ago at news.google.com         
Samsung Biologics eyes new drugmaker acquisitions - Korea Economic Daily
Google News at Macroaxis
over a year ago at news.google.com         
Samsung Biologics has blowout Q3, revenues hit new high - The Korea JoongAng Daily
Google News at Macroaxis
over a year ago at news.google.com         
Seoul shares snap 3-day fall on strong techs, bios won sharply up - Yonhap News Agency
Google News at Macroaxis
over a year ago at news.google.com         
Samsung Biologics banks on antibody drugs as fifth factory progresses - The Korea JoongAng Daily
Google News at Macroaxis
over a year ago at news.google.com         
Listed firms market cap rises about 15 pct this year - Yonhap News Agency
Google News at Macroaxis
over a year ago at news.google.com         
Samsung Biologics raises sales forecast on higher utilization of new plant - koreatimes
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Samsung Biologics that are available to investors today. That information is available publicly through Samsung media outlets and privately through word of mouth or via Samsung internal channels. However, regardless of the origin, that massive amount of Samsung data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Samsung Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Samsung Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Samsung Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Samsung Biologics alpha.

Samsung Biologics Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for Samsung Stock analysis

When running Samsung Biologics' price analysis, check to measure Samsung Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Samsung Biologics is operating at the current time. Most of Samsung Biologics' value examination focuses on studying past and present price action to predict the probability of Samsung Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Samsung Biologics' price. Additionally, you may evaluate how the addition of Samsung Biologics to your portfolios can decrease your overall portfolio volatility.
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Global Correlations
Find global opportunities by holding instruments from different markets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.